Shares of Pfizer Inc. (NYSE:PFE) ended Wednesday session in green amid volatile trading. The shares closed up +0.07 points or 0.20% at $34.84 with 14.82 million shares getting traded. Post opening the session at $34.72, the shares hit an intraday low of $34.68 and an intraday high of $34.89 and the price vacillated in this range throughout the day. The company has a market cap of $211.33 billion and the numbers of outstanding shares have been calculated to be 6.07 billion shares.
Pfizer Inc. (PFE) on September 7, 2016 announced that Dr. Ole Isacson, a world-renowned scientist and thought leader in neurology, will become Chief Scientific Officer of the Neuroscience Research Unit and Senior Vice President, effective September 16. Dr. Isacson is a Professor of Neurology at Harvard Medical School, and will continue to serve in an educational role. He is also a founding director of the Neuroregeneration Institute at McLean Hospital. Dr. Isacson will report directly to Mikael Dolsten, President of Worldwide Research and Development.
Dr. Isacson received his Medical Bachelor and Doctor of Medicine degrees from the University of Lund in Sweden and held a two year postdoctoral fellowship at Cambridge University in England before joining Harvard in 1989. Over the course of two decades, his lab has become known as one of the most recognized academic research centers for Parkinson’s disease and other neurodegenerative disorders.
“Dr. Isacson’s deep expertise in neurodegenerative disorders is well-aligned with our work in Alzheimer’s and Parkinson’s disease, where we are working to advance potential breakthrough therapies to fill the tremendous unmet need that exists for patients,” said Dr. Dolsten. “In addition, his strong ties in the local academic community will be important as our Cambridge site continues to drive collaborations with leading scientific and academic institutions that can help us speed the pace of discovery.”
Shares of AstraZeneca plc (ADR) (NYSE:AZN) ended Wednesday session in green amid volatile trading. The shares closed up -0.09 points or 0.27 % at $33.18 with 4.49 million shares getting traded. Post opening the session at $33.07, the shares hit an intraday low of $32.96 and an intraday high of $33.21 and the price vacillated in this range throughout the day. The company has a market cap of $81.55 billion and the numbers of outstanding shares have been calculated to be 1.26 million shares.
AstraZeneca plc (ADR) (AZN) on September 1, 2016 announced results from the SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol LABA (long-acting beta2-adrenergic agonist) safety study showing patients with controlled and uncontrolled asthma had a comparable risk of serious asthma-related events and a lower risk of asthma exacerbations when formoterol was combined with budesonide versus budesonide alone.
The study compared the safety of formoterol, a LABA, used in combination with budesonide, an inhaled corticosteroid (ICS)–the two active therapies in SYMBICORT pressurized metered dose inhaler (pMDI)–against budesonide (pMDI) to evaluate the risk of serious asthma-related events. These events are defined as a composite endpoint of asthma related events including asthma-related deaths, intubations, and hospitalizations, with time to first serious asthma-related event as the primary endpoint.
The results showed a comparable risk of serious asthma-related events when formoterol was combined with budesonide versus budesonide alone. Based on a predefined non-inferiority margin, the upper limit of the 95% confidence interval (CI) for the hazard ratio (HR) of the primary safety endpoint needed to be less than two. As a result, the findings demonstrated statistical non-inferiority of SYMBICORT to budesonide for time to first serious asthma-related event (HR [1.073], 95% CI, [0.698-1.650]). Furthermore, SYMBICORT therapy resulted in a 16.5% lower risk of asthma exacerbations than budesonide (HR, 0.835; 95% CI, 0.745 to 0.937; P = 0.002).